-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Fifth Yangtze River Delta Liver Disease Summit Forum and Seminar on Multidisciplinary Diagnosis and Treatment of Liver Tumors in 2021 was held in Hefei recently.
Infection diagnosis and treatment
Hepatocellular carcinoma (HCC) is a hot topic discussed at this conference.
"Liver cancer is a malignant disease with a high incidence, high fatality rate, and high recurrence rate.
"Liver cancer is a malignant disease with a high incidence, high fatality rate, and high recurrence rate.
On May 27, 2021, the " Consensus of Chinese Experts on Transformation Therapy of Advanced Hepatocellular Carcinoma Based on Immune Combination Targeting Program (2021 Edition)" (hereinafter referred to as "Consensus") press conference was held in Beijing .
Immune checkpoint inhibitors represented by PD-1/PDL-1 inhibitors, combined with targeted therapy and local treatment, are expected to successfully transform some patients with advanced liver cancer, and improve the prognosis of patients through comprehensive treatment centered on surgery
Professor Lu Shichun of the Department of Hepatobiliary and Pancreatic Surgery of the Chinese People’s Liberation Army General Hospital mentioned that hepatocellular carcinoma accounts for 75%-90% of the total number of primary liver cancers, and up to 39.
Dr.
Professor Li Gong of Beijing Tsinghua Chang Gung University Hospital mentioned that the treatment plan of ICIs combined with AATDs is simple and convenient for patients, even at home, and related adverse reactions can be relieved by themselves or only need to be treated symptomatically.
Professor Bi Xinyu from the Cancer Hospital of the Chinese Academy of Medical Sciences mentioned that surgical treatment of advanced hepatocellular carcinoma after transformation is safe and feasible, but the surgical method is relatively complicated.
Experts also said that immune checkpoint inhibitors (ICIs) combined with anti-angiogenesis targeted drugs (AATDs) to treat advanced hepatocellular carcinoma will also be the breakthrough and main direction for improving the overall 5-year survival rate of the liver cancer population in the next ten years.
This conference was jointly sponsored by the Hepatology Group of the Surgery Branch of the Beijing Medical Association, the Chinese Journal of Hepatobiliary Surgery Committee, and the Hepatobiliary and Pancreatic Disease Prevention and Control Professional Committee of the Chinese Preventive Medicine Association
Professor He Xiaodong from Peking Union Medical College Hospital stated at the meeting that the combination of ICIs and AATDs, or superimposing other applicable local treatments, to form a further three-dimensional transformational treatment plan opened up a new direction for the treatment of advanced hepatocellular carcinoma.
Next, the "Chinese Expert Consensus on Translational Therapy of Advanced Hepatocellular Carcinoma Based on Immune Combined Targeting Program (2021 Edition)" will be promoted nationwide.
Professor Weidong Xiao
Chief Physician of the First Affiliated Hospital of University of Science and Technology of China
Professor, PhD supervisor, PhD
Department of Liver Surgery, First Affiliated Hospital of Chinese University of Science and Technology
Member of International Liver Cancer Association/Member of International Hepatobiliary and Pancreatic Association
Member of the Hepatology Group of the Chinese Medical Association Surgery Branch
Member of the Liver Cancer Group of the Oncology Branch of the Chinese Medical Association
Member of the Liver Cancer Group of the Chinese Society of Liver Diseases
Member of the Standing Committee of the Liver Cancer Professional Committee of the Chinese Anti-Cancer Association
Member of the Standing Committee of the Liver Cancer Professional Committee of the Chinese Medical Doctor Association and Chairman of the Intelligent Diagnosis and Treatment Committee
Standing Committee Member of the Liver Cancer Expert Committee of the Chinese Society of Clinical Oncology
Member of the Standing Committee of the Liver Surgeons Committee of the Chinese Medical Doctor Association Surgeons Branch
Member of the National Cancer Center Liver Cancer Quality Control Expert Committee
Deputy Chairman of the Surgery Branch of Anhui Medical Association and Leader of the Hepatobiliary and Pancreatic Surgery Group
Chairman of the Liver Cancer Professional Committee of Anhui Anti-Cancer Association
Leave a message here